AEB071
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uveitis
Conditions
Uveitis, Posterior Uveitis, Panuveitis
Trial Timeline
Jul 1, 2008 → —
NCT ID
NCT00615693About AEB071
AEB071 is a phase 2 stage product being developed by Novartis for Uveitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00615693. Target conditions include Uveitis, Posterior Uveitis, Panuveitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01430416 | Phase 1 | Completed |
| NCT01402440 | Phase 1 | Terminated |
| NCT00615693 | Phase 2 | Completed |
| NCT00545259 | Phase 1 | Completed |
| NCT00492869 | Phase 1/2 | Completed |
| NCT00416546 | Phase 1 | Completed |
| NCT00409929 | Phase 1 | Completed |
Competing Products
20 competing products in Uveitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| triamcinolone acetonide (Triesence®) | Clearside Biomedical | Phase 1/2 | 33 |
| 4 mg CLS-TA Suprachoriodal Injection | Clearside Biomedical | Phase 3 | 69 |
| Baricitinib + Adalimumab | Eli Lilly | Phase 3 | 77 |
| Ixekizumab Prefilled Syringe | Eli Lilly | Approved | 85 |
| adalimumab | AbbVie | Phase 3 | 77 |
| Adalimumab + Prednisone + Placebo | AbbVie | Phase 3 | 77 |
| Adalimumab + Prednisone + Placebo | AbbVie | Phase 3 | 77 |
| Adalimumab | AbbVie | Approved | 85 |
| FTY720 + Oral Corticosteroid | Novartis | Phase 2 | 52 |
| AIN457 | Novartis | Phase 3 | 77 |
| Myfortic | Novartis | Pre-clinical | 23 |
| AIN457 + AIN457 + Placebo AIN457 | Novartis | Phase 3 | 77 |
| LFG316 + Conventional Therapy | Novartis | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 2 | 52 |
| AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |
| Myfortic + Decortin | Novartis | Phase 3 | 77 |
| AIN457 + AIN 457 + AIN457 | Novartis | Phase 2 | 52 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |